Recent Finacing
Recent Raise
Tune Therapeutics develops gene, cell, and regenerative therapies using the TEMPO epigenome‑editing platform (dCas9+effector) and LNP delivery, advancing its epigenetic silencer Tune‑401 into clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Tune Therapeutics.
